Immix Biopharma (IMMX) Free Cash Flow (2021 - 2026)

Immix Biopharma has reported Free Cash Flow for 6 years, with the latest figure at -$9.9 million in Q1 2026.

• Quarterly Free Cash Flow fell 462.49% year-over-year to -$9.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$32.8 million (down 144.61% YoY) and the FY2025 annual result came in at -$24.7 million, down 56.37% from the prior year.
• Free Cash Flow rose to -$9.9 million in Q1 2026 per IMMX's latest filing, from -$11.2 million in the prior quarter.
• Over five years, Free Cash Flow peaked at -$547066.0 in Q2 2022 and troughed at -$11.2 million in Q4 2025.
• A 5-year average of -$4.1 million and a median of -$3.5 million in 2023 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2022 and 2025: Free Cash Flow slumped 2781.24% in 2022, then soared 57.55% in 2025.
• Over 5 years, Free Cash Flow stood at -$3.9 million in 2022, then soared by 31.08% to -$2.7 million in 2023, then increased by 26.29% to -$2.0 million in 2024, then tumbled by 464.44% to -$11.2 million in 2025, then rose by 11.93% to -$9.9 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$9.9 million, -$11.2 million, and -$6.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.